QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=47BD8608FF341F1D3328BD9EEC561979;jsessionid=A043B438A3B5591667B8740B38982408;jsessionid=42DB9C9F8349EEE44A6CA26A86691324;jsessionid=1855AD6E4F0A8B779B817097441CBE8C;jsessionid=DA3833FEFF4D3D1B1D3E077C2E4ABDD6;jsessionid=CBD3051B46B0EA634661F06764166F75;jsessionid=5931C655C17726278170C3B0F21CD33D (gene)

1. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
2. Missense mutation in ATXN2 gene (c.2860C > T) in an amyotrophic lateral sclerosis patient with aggre…
3. The RNA-binding protein and stress granule component ATAXIN-2 is expressed in mouse and human tissue…
4. Ataxin-2 gene: a powerful modulator of neurological disorders.
5. Antagonistic roles for Ataxin-2 structured and disordered domains in RNP condensation.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=47BD8608FF341F1D3328BD9EEC561979;jsessionid=A043B438A3B5591667B8740B38982408;jsessionid=42DB9C9F8349EEE44A6CA26A86691324;jsessionid=1855AD6E4F0A8B779B817097441CBE8C;jsessionid=DA3833FEFF4D3D1B1D3E077C2E4ABDD6;jsessionid=CBD3051B46B0EA634661F06764166F75;jsessionid=5931C655C17726278170C3B0F21CD33D